Don't miss out on insights from HAYA CEO Samir Ounzain , Michela Coan, Simon Häfliger and Rory Johnson on targeting and engineering #lncRNAs . Dive deeper into this exciting field!🧬
nature.com/articles/s4157…

Targeting and engineering long non-coding RNAs for cancer therapy go.nature.com/49zHhmm #Review by Michela_Coan, Simon Haefliger, Samir Ounzain Samir Ounzain & Rory Johnson University College Dublin

⚡️Pleased to share our latest article reviewing the exciting potential of manipulating or even engineering long noncoding RNAs #lncRNAs to create effective, durable, economical and safe therapies for #cancer :
nature.com/articles/s4157…
with Michela_Coan Samir Ounzain HAYA Therapeutics

👇💡🦋New paper alert from Goldie Michela_Coan !

A genetic element aka a transposable element. Just say it ffs!! 😜🐒
nature.com/articles/s4158…

Throughout history, remarkable women have been pivotal in shaping scientific breakthroughs, proving innovation knows no bounds. Today on UNESCO 🏛️ #Education #Sciences #Culture 🇺🇳 International Day of Women & Girls in Science, we celebrate #WomenInScience ! More on women who changed science: nobelprize.org/womenwhochange…

It was fun to write this with Nadya Dimitrova. We tried to summarize what we've learned about transcription-regulating lncRNAs, including “stabilizer” lncRNAs that work as TF gene rheostats, activating lncRNAs, and emerging roles of lncRNAs in disease rdcu.be/dwqrQ

Great start to #lorneGenome2024 with Ling-Ling Chen on circRNAs as modulators of dsRNA sensor PKR & Joanna W Jachowicz on 3D localization and spreading of ncRNAs on chromatin, including Xist and my faves, TE-derived RNAs. RNAs are busy busy molecules!

It could actually be the first example of a human phenotype unequivocally ascribed to disruption of a lncRNA unit rather than an enhancer, because Chaserr mutations don’t cause gene silencing

Read more about this in our very recent review
rdcu.be/dwqrQ

Chaserr lncRNA mutations cause a neurodevelopmental phenotype

Its groundbreaking because Chaserr is an exemplar of lncRNAs regulating dosage-sensitive gene expression. It was clear from mouse genetics that these “stabilizer” lncRNAs are essential, and now also the case in humans

I am biased but I think this is a really important paper for those interested in conducting heart failure trials. medrxiv.org/content/10.110…

Long non-coding RNAs comprise a large part of the genome, yet loss of one copy (haploinsufficiency) of a lncRNA is not known to cause a human disease. Read our preprint to learn how deletions of the lncRNA CHASERR cause a severe neurodevelopmental disorder.medrxiv.org/content/10.110…

We presented #SCMR2024 an interim look at patients with #oHCM who were treated with aficamten for 1 year and underwent serial #WhyCMR assessment as part of the #FOREST #HCM trial
# #CardioTwitter

Latest work from GOLD Lab , #TransCistor , a method for classifying cis-regulatory #lncRNAs in a quantitative manor. Hopefully it will be useful for people and provide a global view of these fascinating inhabitants of our #genome . Thanks to excellent tireless team!

Did you miss HAYA Scientific Advisor Sudhir Agrawal at #OTS23 ? One of this year's Lifetime Achievement Awardees, he presented on the evolution of RNA-based therapeutics, his career and lessons learned along the way. Check it out now!

youtube.com/watch?v=3fIXkk…

Today, our CTO Daniel Blessing had the honor of representing HAYA at a meeting of Swiss President Alain Berset & French President Emmanuel Macron. HAYA was proud to present & take part in an invigorating discussion about Swiss innovation & working across French-Swiss borders.

#HAYAteam members from both sides of the Atlantic recently gathered at our Lausanne🇨🇭headquarters to catalyze collaborations & meet the new faces from both offices. At HAYA, we know that highly integrated & interactive collaborative teams are key to cutting-edge discovery! 🚀

HAYA's pleased to announce the appointment of Dr. James G. Karras as our new Vice President, Translation. With over 20 years of experience directing immunology & drug discovery programs at leading pharma companies, he'll be instrumental in moving our discoveries into the clinic.

A sweet update! New research from HAYA friend/collaborator Phillip Grote & co-authors—including CEO Samir Ounzain (Samir Ounzain)—in Nature Communications demonstrates Sweetheart (Swhtr) #lncRNA 's essential role in tissue adaptation process after myocardial infarction: nature.com/articles/s4146…

We were close to stop working on the Sweetheart lncRNA, but Samir Ounzain encouraged us to look into a stress model. Well, this paid off.....